AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma
NCT01085214
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
37
Enrollment
NIH
Sponsor class
Conditions
Recurrent Plasma Cell Myeloma
Refractory Plasma Cell Myeloma
Interventions
OTHER:
Laboratory Biomarker Analysis
DRUG:
Selumetinib
Sponsor
National Cancer Institute (NCI)